These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37144750)

  • 1. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
    Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
    J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC.
    Fan Y; He L; Yang H; Wang Y; Su J; Hou S; Luo Y; Jiang X
    J Magn Reson Imaging; 2023 Jun; 57(6):1778-1787. PubMed ID: 36165534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
    Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
    Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface.
    Fan Y; Zhao Z; Wang X; Ai H; Yang C; Luo Y; Jiang X
    Radiol Med; 2022 Dec; 127(12):1342-1354. PubMed ID: 36284030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Habitat-Based Radiomics for Predicting EGFR Mutations in Exon 19 and 21 From Brain Metastasis.
    Yang C; Fan Y; Zhao D; Wang Z; Wang X; Wang H; Hu Y; He L; Zhang J; Wang Y; Liu Y; Sha X; Su J
    Acad Radiol; 2024 Sep; 31(9):3764-3773. PubMed ID: 38599906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
    Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
    Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
    Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
    Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
    Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial for "Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis".
    Luo Q; Zhou XJ
    J Magn Reson Imaging; 2023 Dec; 58(6):1848-1849. PubMed ID: 37459283
    [No Abstract]   [Full Text] [Related]  

  • 10. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.
    Lu J; Ji X; Liu X; Jiang Y; Li G; Fang P; Li W; Zuo A; Guo Z; Yang S; Ji Y; Lu D
    Sci Rep; 2024 Jan; 14(1):446. PubMed ID: 38172228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
    Li Y; Lv X; Wang B; Xu Z; Wang Y; Sun M; Hou D
    Acad Radiol; 2023 Sep; 30(9):1887-1895. PubMed ID: 36586758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
    Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
    Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-liver interface in MRI of liver metastasis enables prediction of EGFR mutation in patients with lung cancer: A proof-of-concept study.
    Hou S; Wang H; Wang X; Chen H; Zhou B; Meng R; Sha X; Chang S; Wang H; Jiang W
    Med Phys; 2024 Feb; 51(2):1083-1091. PubMed ID: 37408393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
    Fan Y; Dong Y; Wang H; Wang H; Sun X; Wang X; Zhao P; Luo Y; Jiang X
    Eur Radiol; 2022 Oct; 32(10):6739-6751. PubMed ID: 35729427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
    BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
    Zhou J; Li Y; Zhang Y; Dai H; Guo S
    Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.